Pantop%2525252525252525252525252520d

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly binding to the H+/K+-ATPase enzyme system in gastric parietal cells. It is available in oral (delayed-release tablets, suspension) and intravenous (IV) formulations. ## Primary Indications * Erosive esophagitis associated with GERD. * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome). * Short-term treatment of GERD symptoms. ## Adult Dosing * **Erosive Esophagitis:** 40 mg orally or IV once daily for up to 8 weeks. * **Maintenance of Healing:** 40 mg orally once daily. * **Hypersecretory Conditions:** Starting dose is 40 mg twice daily. Doses up to 240 mg/day have been utilized; titration should be based on clinical response and acid output. * **IV Bolus:** 40 mg (as a 15-minute infusion) or 80 mg (as a 15-minute infusion) twice daily for certain GI hemorrhage protocols (note: clinical practice regarding PPIs in GI bleeds varies significantly by local institutional protocol). ## Pediatric Dosing * **GERD (5 years and older):** * 15 kg to <40 kg: 20 mg once daily. * 40 kg or greater: 40 mg once daily. * *Note: Safety and efficacy are not established for children under 5 years of age.* ## Dose Adjustments * **Hepatic Impairment:** No initial dose adjustment required for mild to moderate impairment. Severe impairment may require dose reduction; monitor closely. * **Renal Impairment:** No dose adjustment necessary. * **Elderly:** No routine adjustment based on age alone. ## Contraindications * Known hypersensitivity to pantoprazole or other substituted benzimidazoles (e.g., omeprazole, lansoprazole). * Concurrent use with rilpivirine-containing products. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain, injection site reactions (IV). * **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, cutaneous/systemic lupus erythematosus, and increased risk of bone fractures (long-term, high-dose use). ## Key Drug Interactions * **pH-Dependent Drugs:** Reduces absorption of atazanavir, nelfinavir, and ketoconazole. * **Methotrexate:** PPIs may increase serum methotrexate levels, particularly in high-dose therapy. * **Warfarin:** Monitor INR frequently; potential for altered metabolism or absorption. * **CYP2C19 Inhibitors/Inducers:** While pantoprazole has a lower affinity for CYP450 than other PPIs, monitor for pharmacokinetic interactions. ## Monitoring * **Baseline/Long-term:** Magnesium levels (if on long-term therapy or concomitant diuretics), Vitamin B12 levels. * **Clinical:** Monitor for signs of *C. difficile* infection (unresolved diarrhea, fever). * **IV:** Monitor infusion site for thrombophlebitis. ## Clinical Pearls * **Administration:** Tablets should be swallowed whole; do not crush or chew. IV formulation requires reconstitution and dilution. * **Tapering:** Long-term users may experience rebound hypersecretion upon discontinuation; consider a gradual taper. * **Clinical Utility:** Overuse of PPIs is common; ensure a clear indication for therapy and re-evaluate the need for chronic treatment regularly. * **Local Protocol:** Specific dosing for inpatient stress ulcer prophylaxis (SUP) or active gastrointestinal bleeding varies by facility. Always consult your institution’s specific guidelines. *** **Disclaimer:** This information is for educational purposes only. Drug dosing, contraindications, and interaction profiles frequently change. Always verify current prescribing information through official FDA labels, the manufacturer’s package insert, or institutional pharmacy resources before prescribing or administering medication.